- In Bloomberg Law, Health Care Partner Examines Final Rule on Drugmaker TV Ad Price Disclosures (May 14, 2019)
- In Law360, Life Sciences Attorneys Examine FDA Draft Guidance on Medical Device Inspections (May 13, 2019)
- In Pink Sheet, Life Sciences Partner Discusses Drug Pre-Approval Promotion (March 28, 2019)
- Outlook 2019 Teleconference: Washington, D.C. Updates and Insights on Life Sciences and Health Care (January 23, 2018)
- Cross-Practice Team Authors Law360 Article on FDA’s Right to Try Act and Expanded Access Pathway (December 18, 2018)
- FDA Regulatory Attorney Discusses Enforcement Priorities & Whistleblower Lawsuits in Medtech Insight (November 15, 2018)
- Ropes & Gray Adds Experienced FDA Counsel in Washington, D.C. (October 22, 2018)
- Health Care Partner Addresses FDA Bid to Lower Drug Prices in The Washington Post (July 19, 2018)
- In Law360, Attorneys Examine FDA Final Guidance on Payor Communications and Communications Consistent with Labeling (June 27, 2018)
- In Inside Health Policy and Medical Marketing & Media, Life Sciences Partner Addresses FDA Final Guidance on Payor Communications and Communications Consistent with the Labeling (June 15, 2018)
- In Medical Marketing & Media, Life Sciences Partner Addresses Healthcare Marketing Changes Under Trump Administration (May 29, 2018)
- In Bloomberg Law, Life Sciences Co-Chair Addresses FDA Medical Device Clearance Proposal (April 17, 2018)
- Podcast - Developments in FDA & DOJ Regulation and Enforcement of Manufacturer Communications (April 12, 2018)
- Event - Outlook 2018 Teleconference: The Trump Administration’s Impact on Life Sciences and Health Care—the First Year
- The Latest FDA Move To Limit Digital Health Software Regs (December 22, 2017)
- FDA Issues Draft Guidances to Scale Back Regulation of Digital Health Software (December 13, 2017)
- In Law360, Life Sciences and Corporate Team Examines FDA Move to Limit Digital Software Regulations (December 22, 2017)
- FDA Issues Three Key Documents Relating to Medical Product Manufacturer Communications (January 31, 2017)
- Event - Outlook 2017: The New Administration and Its Impact on Life Sciences and Health Care (January 25, 2017)
- Health Care and FDA Changes Expected Under Trump Administration (January 11, 2017)
- “The New FDA: Product Development, Pricing and Beyond,” JD Supra Business Advisor (January 6, 2017)
- “The New U.S. Department of Health and Human Services: Tom Price and Value-Based Health Care,” JD Supra Business Advisor (January 6, 2017)
- “Life Sciences Legislation and Regulation to Watch In 2017,” Law360 (January 2, 2017)
- Podcast - The New FDA: Product Development, Pricing and Beyond (December 22, 2016)
- 21st Century Cures Act – Provisions Relating to Development Incentives for Certain Classes of Drugs (December 13, 2016)
- 21st Century Cures Act – Provisions Relating to Digital Health (December 13, 2016)
- 21st Century Cures Act – Provisions Relating to Reimbursement & Fraud and Abuse (December 13, 2016)
- 21st Century Cures Act – Provisions to Promote Drug Development (December 13, 2016)
- 21st Century Cures Act – Provisions Relating to Medical Device Innovation (December 13, 2016)
- 21st Century Cures Act – Provisions Relating to Regulation of Clinical Research (December 13, 2016)
- Podcast - FDA Holds Public Hearing on Manufacturer Communication of Scientific and Medical Information (November 14, 2016)
Cookie Settings
